Back

Spatiotemporal profiling reveals the role of inflammatory niche in driving prostate cancer

Nazir, A.; Wang, H.; Lu, Z.; Lau, J.; Peale, F.; Jesudason, R.; Connolly, K. A.; Andrusivova, Z.; Lau, J.; Gierke, S.; Peng, L.; Chan, S.; Jiang, J.; Rost, S.; Lubeck, E.; Simone, M. D.; Daniel, B.; McGinnis, L. M.; Maddalo, D.; Joshi, N. S.; Garraway, L. A.; Regev, A.

2026-04-22 cancer biology
10.64898/2026.04.19.719485 bioRxiv
Show abstract

Prostate cancer (PCa) is a lethal malignancy that displays profound resistance to immune checkpoint blockade (ICB), via mechanisms that are poorly understood. Here, we investigate the causes of CD8 T cell exhaustion and mechanisms of tumor progression in a PCa animal model, by single cell and spatial profiling, along a time course, following orthotopic transplantation of RB1/TP53/PTEN-deficient mouse organoids, competent to express neoantigens. The resulting tumors were castration resistant, consisting of largely basal and L2 malignant cells with upregulated inflammatory gene programs, and a specific spatial distribution of macrophages, cancer associated fibroblast (CAF) subtypes, and CD8 T-cells that was not previously reported. Using Zman-seq, we demonstrate that the effector function of tumor-infiltrating CD8 T cells was rapidly impaired as early as 24hrs after their infiltration, likely driven by signals from proinflammatory macrophages, Ccl2-Jak2+ inflammatory CAFs, and malignant basal cells, thus driving resistance to ICB. Interestingly, dual blockade of JAK1/2 and PD1 induced potent anti-tumor effects in tumor epithelial cells, decreased malignant epithelial cells and pro-inflammatory macrophages, and increased the proportion of normal (Pi16+) fibroblasts in the TME. Our results underscore the therapeutic potential of targeting JAK1/2 to enhance the efficacy of ICB, providing a rationale for clinical investigation of this combination in PCa.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Nature Communications
4913 papers in training set
Top 12%
14.1%
2
Cell Reports
1338 papers in training set
Top 2%
12.1%
3
Oncogene
76 papers in training set
Top 0.1%
9.0%
4
Cancer Cell
38 papers in training set
Top 0.3%
4.1%
5
Journal of Clinical Investigation
164 papers in training set
Top 0.9%
3.9%
6
Cancer Discovery
61 papers in training set
Top 0.5%
3.9%
7
Cancer Research
116 papers in training set
Top 0.9%
3.5%
50% of probability mass above
8
Advanced Science
249 papers in training set
Top 6%
3.5%
9
Clinical Cancer Research
58 papers in training set
Top 0.6%
2.7%
10
eLife
5422 papers in training set
Top 36%
2.0%
11
JCI Insight
241 papers in training set
Top 3%
1.9%
12
Science Advances
1098 papers in training set
Top 15%
1.9%
13
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.6%
1.7%
14
Cancer Research Communications
46 papers in training set
Top 0.5%
1.7%
15
Cell Reports Medicine
140 papers in training set
Top 4%
1.7%
16
iScience
1063 papers in training set
Top 16%
1.7%
17
Genome Medicine
154 papers in training set
Top 5%
1.6%
18
Molecular Cancer Therapeutics
33 papers in training set
Top 0.4%
1.5%
19
Cell Stem Cell
57 papers in training set
Top 1%
1.5%
20
Molecular Oncology
50 papers in training set
Top 0.5%
1.3%
21
Journal of Experimental Medicine
106 papers in training set
Top 3%
1.2%
22
Developmental Cell
168 papers in training set
Top 10%
1.2%
23
Cell
370 papers in training set
Top 15%
0.9%
24
EMBO Molecular Medicine
85 papers in training set
Top 4%
0.8%
25
Cell Death & Disease
126 papers in training set
Top 2%
0.8%
26
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 45%
0.7%
27
Journal of Experimental & Clinical Cancer Research
25 papers in training set
Top 0.3%
0.7%
28
Frontiers in Oncology
95 papers in training set
Top 4%
0.6%
29
The EMBO Journal
267 papers in training set
Top 7%
0.6%
30
Cancers
200 papers in training set
Top 5%
0.6%